We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Low-Cost, Ultra-Fast DNA Sequencing Technology Developed

By LabMedica International staff writers
Posted on 23 Jun 2010
Sequencing DNA could get a lot faster and less expensive--and thus closer to routine use in clinical diagnostics--due to a new method developed by US researchers. More...
The team has demonstrated the first use of solid-state nanopores (tiny holes in silicon chips that detect DNA molecules as they pass through the pore) to read the identity of the four nucleotides that encode each DNA molecule. Moreover, the researchers have shown the viability of an innovative, more efficient method to detect single DNA molecules in nanopores.

"We have employed, for the first time, an optically-based method for DNA sequence readout combined with the nanopore system,” said Boston University biomedical engineer Dr. Amit Meller, who collaborated with other researchers at Boston University (MA, USA), and at the University of Massachusetts Medical School (Worcester, MA, USA). "This allows us to probe multiple pores simultaneously using a single fast digital camera. Thus, our method can be scaled up vastly, allowing us to obtain unprecedented DNA sequencing throughput.”

The research was published online May 11, 2010, in the journal Nano Letters. The U.S. National Institutes of Health (Bethesda, MD, USA) are currently considering a four-year grant application to further advance Dr. Meller's nanopore sequencing project.

This low-cost, ultra-fast DNA sequencing could transform both healthcare and biomedical research, and lead to major advances in drug development, preventative medicine, and personalized medicine. By gaining access to the entire sequence of a patient's genome, a physician could determine the probability of that patient developing a specific genetic disease.

The researcher's findings show that nanopores, which can analyze extremely long DNA molecules with superior accuracy, are uniquely positioned to compete with current, third-generation DNA sequencing methods for cost, speed, and precision. Unlike those applications, the new nanopore method does not rely on enzymes whose activity limits the rate at which DNA sequences can be read.

"This puts us in the unique advantageous position of being able to claim that our sequencing method is as fast as the rapidly evolving photographic technologies,” said Dr. Meller. "We currently have the capability of reading out about 200 bases per second, which is already much faster than other commercial third-generation methods. This is only the starting point for us, and we expect to increase this rate by up to a factor of four in the next year.”

Licensing intellectual property from Boston University and Harvard University (Cambridge, MA, USA), Dr. Meller and his collaborators recently founded NobleGen Biosciences to develop and commercialize nanopore sequencing based on the new method. "I believe that it will take three to five years to bring cheap DNA sequencing to the medical marketplace, assuming an aggressive research and development program is in place,” said Dr. Meller.

Related Links:
Boston University
University of Massachusetts Medical School


Gold Member
Troponin T QC
Troponin T Quality Control
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Automated Microscope
dIFine
New
Silver Member
Autoimmune Hepatitis Test
LKM-1-Ab ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: New research brings hope for improved early detection of pancreatic cancer (Photo courtesy of Adobe Stock)

New Biomarker Panel to Enable Early Detection of Pancreatic Cancer

Pancreatic cancer (PC) has one of the worst prognoses globally, with only 13% of diagnosed patients surviving for five years or more. In Ireland, there are about 900 cases of pancreatic cancer annually,... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.